GI Signals - Hepatology

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.

Sat, 18 Jul 2026 20:04:34 +0000

The lancet. Gastroenterology & hepatology. Consider zalfermin 30 mg co-administered with semaglutide 2.4 mg weekly as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis (F2-F4c), pending phase 3 confirmation of efficacy and safety. Monitor for adverse effects as part of clinical trials or post-marketing surveillance.

IgA-Enriched Phenotype Predicts Liver-Related Events in MASLD.

Sat, 18 Jul 2026 20:04:34 +0000

Journal of hepatology. Consider measuring serum IgA levels in MASLD patients for additional risk stratification, particularly in those without advanced fibrosis but with unexplained disease progression. No clinical action yet: the therapeutic implications of IgA-targeted interventions remain investigational.

A machine learning approach to non-invasive prediction of hepatic decompensation in compensated advanced chronic liver disease: the CIRI model.

Sat, 18 Jul 2026 20:04:34 +0000

Journal of hepatology. Consider using the CIRI model as a non-invasive alternative to HVPG for stratifying decompensation risk in cACLD patients, particularly where HVPG or LSM are unavailable. No clinical action yet: requires further validation before widespread adoption.

Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality.

Sat, 18 Jul 2026 20:04:34 +0000

Gut. Consider cryptogenic SLD as a distinct high-risk phenotype in lean patients (BMI <25 kg/m²) without CMRFs. Monitor these patients for liver injury using non-invasive fibrosis assessment tools (e.g., FIB-4, VCTE, MRE) and consider closer follow-up despite the absence of traditional metabolic risk factors.

Recompensation of decompensated cirrhosis in a spectrum of metabolic-dysfunction-related steatotic liver disease, with PEth-corroborated alcohol abstinence and modification of cardiometabolic risk factors.

Sat, 18 Jul 2026 20:04:34 +0000

Hepatology (Baltimore, Md.). For decompensated MASLD/MetALD cirrhosis, prioritize PEth-confirmed alcohol abstinence (PEth >200 ng/mL indicates heavy chronic use), weight loss ≥10%, glycemic control, and variceal screening. Monitor for recompensation potential, especially in patients without large varices or MetALD etiology, where mortality is higher (22.6% vs. 12.0% in MASLD, p=0.011).

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Thu, 09 Jul 2026 16:47:07 +0000

Journal of hepatology. Prognostic scores may help identify patients unlikely to benefit from standard adherence support. For elevated-risk patients, alternative strategies are needed as current adherence support did not improve outcomes.

Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial.

Thu, 09 Jul 2026 16:47:07 +0000

Journal of gastroenterology and hepatology. Continue standard UDCA dose (13-15 mg/kg/day) in PBC patients with complete biochemical response; reduction to 5 mg/kg/day is unsafe due to high relapse risk. Consider monitoring 10 mg/kg/day cautiously in select patients (future studies needed). Do not reduce below 10 mg/kg/day in remission.